Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-16T20:16:00.125Z Has data issue: false hasContentIssue false
  • English
  • Français

Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial

Published online by Cambridge University Press:  24 June 2014

Ho-Kyoung Yoon ,
Yong-Ku Kim ,
Changsu Han ,
Young-Hoon Ko ,
Heon-Jeong Lee ,
Do-Young Kwon  and
Leen Kim
Ho-Kyoung Yoon
Affiliation:
Department of Psychiatry, College of Medicine, Korea University, Seoul, South Korea
Yong-Ku Kim
Affiliation:
Department of Psychiatry, College of Medicine, Korea University, Seoul, South Korea
Changsu Han
Affiliation:
Department of Psychiatry, College of Medicine, Korea University, Seoul, South Korea
Young-Hoon Ko
Affiliation:
Department of Psychiatry, College of Medicine, Korea University, Seoul, South Korea
Heon-Jeong Lee
Affiliation:
Department of Psychiatry, College of Medicine, Korea University, Seoul, South Korea
Do-Young Kwon
Affiliation:
Department of Neurology, College of Medicine, Korea University, Seoul, South Korea
Leen Kim*
Affiliation:
Department of Psychiatry, College of Medicine, Korea University, Seoul, South Korea
*
Professor Leen Kim, Department of Psychiatry, College of Medicine, Korea University Anam Hospital, Anam-Dong, Sungbuk-Gu, Seoul 136-705, South Korea. Tel: +82 2 920 5815; Fax: +82 2 927 2836; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Extract

Yoon H-K, Kim Y-K, Han C, Ko Y-H, Lee H-J, Kwon D-Y, Kim L. Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial.

Objective: Delirium is a life-threatening neuropsychiatric syndrome characterised by disturbances in consciousness, attention, cognition and perception. Antipsychotics are considered the drugs of choice in managing the symptoms of delirium. Paliperidone is a benzisoxazole derivative and the principal active metabolite of risperidone. In this study, we aimed to evaluate the efficacy of paliperidone for the treatment of delirium.

Methods: A prospective open-label study of paliperidone for delirium treatment was performed with 6-day follow-up. Fifteen patients who met Diagnostic and Statistical Manual of Mental disorders, Fourth Edition criteria for delirium and had a score of 13 on the Delirium Rating Scale were recruited. The starting dose was 3 mg once a day and the dose was adjusted depending on the status of delirium. Daily assessments of the severity of delirium were evaluated using Memorial Delirium Assessment Scale (MDAS).

Results: The mean daily maintenance dose of paliperidone was 3.75 ± 1.06. The MDAS scores before and after treatment (day 7) were 23.60 ± 6.31 and 11.33 ± 5.45 (t = 6.78, p < 0.001), respectively. The intensity of delirium showed a statistically significant reduction in MDAS scores from the first day of treatment. No serious adverse effects were observed, and none of the patients discontinued paliperidone because of adverse effects.

Conclusions: This study shows that low-dose paliperidone is effective in reducing behavioural disturbances and symptoms in delirium and is well tolerated in delirious patients. This trial is an open-label study with a small sample size, and further controlled studies will be necessary.

Keywords

deliriumDRSMDASpaliperidone
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 23 , Issue 4 , August 2011 , pp. 179 - 183
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.American Psychiatric Association. Practice guideline for the treatment of patients with delirium. American Psychiatric Association. Am J Psychiatry 1999;156:1–20.Google Scholar
2.Michaud, L, Büla, C, Berney, A et al. Delirium: guidelines for general hospitals. J Psychosom Res 2007;62:371–383.Google Scholar
3.Meagher, DJ.Delirium: optimising management. BMJ 2001;322:144–149.Google Scholar
4.Peritogiannis, V, Stefanou, E, Lixouriotis, C, Gkogkos, C, Rizos, D.Atypical antipsychotics in the treatment of delirium. Psychiatry Clin Neurosci 2009;63:623–631.CrossRefGoogle ScholarPubMed
5.Han, C-S, Kim, Y-K.A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004;45:297–301.Google Scholar
6.Rea, R, Battistone, S, Fong, J, Devlin, J.Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients. Pharmacotherapy 2007;27:588–594.CrossRefGoogle ScholarPubMed
7.Schwartz, T, Masand, P.The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 2002;43:171–174.Google Scholar
8.Richelson, E, Souder, T.Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29–39.Google Scholar
9.Janssen Pharmaceutica Products L. Invega (paliperidone) extended-release tablets, package insert. Titusville, 2007.Google Scholar
10.Ozbolt, L, Paniagua, M, Kaiser, R.Atypical antipsychotics for the treatment of delirious elders. J Am Med Dir Assoc 2008;9:18–28.Google Scholar
11.Prakanrattana, U, Prapaitrakool, S.Efficacy of risperidone for prevention of postoperative delirium in cardiac surgery. Anaesth Intensive Care 2007;35:714–719.CrossRefGoogle ScholarPubMed
12.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington DC: American Psychiatric Press, 1994.Google Scholar
13.Trzepacz, PT, Baker, RW, Greenhouse, J.A symptom rating scale for delirium. Psychiatry Res 1988;23:89–97.CrossRefGoogle ScholarPubMed
14.Breitbart, W, Rosenfeld, B, Roth, A, Smith, MJ, Cohen, K, Passik, S.The Memorial Delirium Assessment Scale. J Pain Symptom Manage 1997;13:128–137.Google Scholar
15.Rosen, J, Sweet, RA, Mulsant, BH, Rifai, AH, Pasternak, R, Zubenko, GS.The Delirium Rating Scale in a psychogeriatric inpatient setting. J Neuropsychiatry Clin Neurosci 1994;6:30–35.Google Scholar
16.Canuso, C, Youssef, E, Bossie, C, Turkoz, I, Schreiner, A, Simpson, G.Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 2008;23:209–215.Google Scholar
17.Canuso, CM, Bossie, CA, Turkoz, I, Alphs, L.Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophr Res 2009;113:56–64.CrossRefGoogle ScholarPubMed
18.Marino, J, Caballero, J.Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy 2008;28: 1283–1298.Google Scholar
19.Tueth, MJ.Emergencies caused by side effects of psychiatric medications. Am J Emerg Med 1994;12:212–216.Google Scholar
20.Tune, L.The role of antipsychotics in treating delirium. Curr Psychiatry Rep 2002;4:209–212.Google Scholar
21.Tune, LE.Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry 2000;5: 149–153.Google Scholar
22.Schotte, A, Janssen, PF, Gommeren, W et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124:57–73.Google Scholar
23.Leysen, JE, Janssen, PM, Megens, AA, Schotte, A.Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994;55(Suppl.):5–12.Google ScholarPubMed
24.Megens, AA, Awouters, FH, Schotte, A et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 1994;114:9–23.Google Scholar
25.Luthringer, R, Staner, L, Noel, N et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 2007;22:299–308.Google Scholar
26.Miller, D.Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004; 6:3–7.Google Scholar
27.Vermeir, M, Naessens, I, Remmerie, B et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008;36: 769–779.Google Scholar